Navigation Links
Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research

ALBANY, New York, July 25, 2014 /PRNewswire/ --

According to a new market report published by Transparency Market Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and Human Insulin) - Industry Analysis, Size, Share, Growth, Trends and Forecast (Value and Volume), 2013 - 2019", the global insulin market was valued at USD 19.99 billion in 2012 and is expected to grow at a CAGR of 6.1% from 2013 to 2019 to reach USD 32.24 billion in 2019.

Browse the full Global and China Insulin Market Report with TOC at

Rising prevalence of diabetes is one of the serious healthcare concerns on a global level. Insulin is a hormone secreted by pancreas to absorb the blood sugar. However, in diabetes, it is either not possible for the body to secrete insulin (type-1) or to utilize secreted insulin to metabolize glucose (type-2). Insulin deficiency in diabetic patients is the most important factor driving the insulin market globally.  Rising prevalence of diabetes and extensive R&D activities are the other key factors boosting growth in the insulin market. No permanent cure has been invented for diabetes, thus the evolution of insulin therapy has emerged as an indispensible treatment therapy for type-1 diabetes patients.

The global and China insulin market is segmented based on source and mode of action. The insulin market by source is categorized as modern insulin and human insulin. The modern insulin segment is expected to grow at the fastest rate during the forecast period from 2013 to 2019, globally as well as in China. The insulin market by mode of action is segmented into rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Due to advantages over other derivatives, the long-acting derivatives segment is expected to grow rapidly during the forecast period. The segment held the largest share of 42.77% of the total market in 2012. It is expected to be the largest segment by the end of 2019. Rapid-acting insulin was the second largest segment in 2012. Other segments such as premixed, intermediate-acting and short-acting insulin derivatives are expected to lose market share during the forecast period. This is mainly due to low patient preference and lack of R&D in these segments. Pharmaceutical companies have concentrated their R&D strategies towards long-acting and rapid-acting derivatives development, which would boost market growth.

Browse All Market Research Press Releases at:

The rapid-acting, long-acting and premixed derivatives segments are the most important segments in China. Growth in these segments is mainly attributed to rising population of type-1 diabetes and growing tendency of type-2 diabetes patients to use insulin as a therapeutic agent.

The insulin market in China is expected to grow steadily due to extensive R&D activities for the development of new insulin analogs and formulations that can be administered via different routes. Various products such as LY2605541 (Eli Lilly and Company), MK-1293 (Merck & Co., Inc.), NN1218 (Novo Nordisk A/S) and Afrezza (MannKind Corporation) are under pipeline studies and are expected to enter the market during the forecast period. Due to these new formulations, the market is likely to grow steadily during the forecast period.

The insulin market is highly consolidated and dominated by select players operating on a global level such as Novo Nordisk A/S, Eli Lilly and Company, and Sanofi. In China, local and regional players such as Shanghai Fosun Pharmaceuticals Pvt. Ltd. and Tonghua Dongbao also contribute to the insulin market.

Related & Recently Published Reports by Transparency Market Research 

The global and China insulin market is segmented as follows: 

  • Global and China Insulin Market, by Mode of Action 
    • Rapid-Acting
    • Short-Acting
    • Intermediate-Acting
    • Premixed
    • Long-Acting

Browse the full Global and China Insulin Market Report with TOC at

  • Global and China Insulin Market, by Source 
    • Modern Insulin
    • Human Insulin

Browse All Pharmaceutical Market Research Reports @

About Us  

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Ms. Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453



Company Blog:


Browse Press Release of Global and China Insulin Market at @

Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon
2. Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019
3. Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020
4. Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical
5. Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report
6. Emulsifiers - Global Strategic Business Report: Updated 2014 Report
7. Global Digital X-Ray Market 2018 Analysis and Forecast In New Research Report Available at
8. Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018
9. Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare
10. Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020
11. Global Coronary Stents Market 2014-2018: Key Vendors are Abbott, Boston Scientific, Medtronic and Terumo
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
Breaking Medicine News(10 mins):